Phase 2 cohort: To evaluate the effect of MK-4575 versus placebo on pulmonary vascular resistance from baseline to week 12. Phase 3 Cohort: To evaluate the effects of MK-5475 versus placebo on 6 minute walk test distances from baseline to week 12.
University of Colorado Hospital
David Badesch, MD
Protocol Number: 21-2564
More information available at ClinicalTrials.gov: NCT04732221
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers